

1 **Title page**

2 **Evaluation of seven different rapid methods for nucleic acid detection of SARS-COV-2 virus**

3 **Running title: Rapid methods for nucleic acid detection of SARS-COV-2 virus**

4 **Authors' details**

5 1.Dr. Sally A. Mahmoud (Corresponding author)

6 Director, Biogenix Lab G42, Abu Dhabi, UAE

7 Email ID: [sally.abdulla@g42.ai](mailto:sally.abdulla@g42.ai)

8 2.Ms. Esra Ibrahim

9 Quality Manager, Biogenix Lab G42, Abu Dhabi, UAE

10 Email ID: [esra.ibrahim@g42.ai](mailto:esra.ibrahim@g42.ai)

11 3.Dr. Subhashini Ganesan

12 Research Assistant, G42 Healthcare, UAE

13 Email ID: [Subhashini.g@g42.ai](mailto:Subhashini.g@g42.ai)

14 4.Dr. Bhagyashree Thakre

15 Specialist Pathologist, Biogenix Lab G42, Abu Dhabi, UAE

16 Email ID: [bhagyashree.thakre@g42.ai](mailto:bhagyashree.thakre@g42.ai)

17 5.Dr.Juliet George Teddy

18 Specialist Pathologist, Biogenix Lab G42, Abu Dhabi, UAE

19 Email ID : [juliet.teddy@g42.ai](mailto:juliet.teddy@g42.ai)

20 6.Mrs.Preeti Raheja

21 Quality Manager, Biogenix Lab G42, Abu Dhabi, UAE

22 Email ID: [Preety.Raheja@g42.ai](mailto:Preety.Raheja@g42.ai)

23 7.Dr.Walid Abbas Zaher

24 Chief Research Officer, G42 Healthcare, UAE

25 Email ID : [Walid.Zaher@g42.ai](mailto:Walid.Zaher@g42.ai)

26

27 **Main manuscript**

28 **Abstract**

29 Background

30 In the current COVID-19 pandemic there is mass screening of SARS-CoV-2 happening round the  
31 world due to the extensive spread of the infections. There is a high demand for rapid diagnostic  
32 tests to expedite identification of cases and to facilitate early isolation and control spread. Hence  
33 this study evaluates seven different rapid nucleic acid detection assays that are commercially  
34 available for SARS- CoV- 2 virus detection.

35 Methods

36 Nasopharyngeal samples were collected from 4859 participants and were tested for SARS-CoV-2  
37 virus by the gold standard RT-PCR method along with one of these seven rapid methods of  
38 detection. Evaluation of the rapid nucleic acid detection assays was done by comparing the results  
39 of these rapid methods with the gold standard RT-qPCR results for SARS-COV-2 detection.

40 Results

41 AQ-TOP had the highest sensitivity (98%) and strong kappa value of 0.943 followed by  
42 Genechecker and Abbot ID NOW. The POCKIT (ii RT-PCR) assay had the highest test accuracy  
43 of 99.29% followed by Genechecker and Cobas Liat. Atila iAMP showed the highest percentage  
44 of invalid reports (35.5%) followed by AQ-TOP with 6% and POCKIT with 3.7% of invalid  
45 reports.

46 Conclusion

47 Genechecker system, Abbott ID NOW and Cobas Liat, were found to have best performance and  
48 agreement when compared to the standard RT-PCR for COVID-19 detection. With further  
49 research, these rapid tests have the potential to be employed in large scale screening of COVID-  
50 19.

51 Keywords: COVID-19; SARS-CoV-2; rapid tests; nucleic acid tests

## 52 **Background**

53 The COVID-19 pandemic has affected more than 112 million people worldwide and continues to  
54 spread and remains a public health challenge. [1] The real-time reverse-transcription PCR (RT-  
55 PCR) remains the gold standard for testing SARS- COV- 2 and is approved by both the WHO and  
56 CDC. But this method requires a well-established lab set up, expensive instruments, well trained  
57 and skilled manpower and long hours. In the current scenario of the pandemic, with such large  
58 numbers being affected conducting these tests with limited lab capacities is challenging. [2] The  
59 lab facilities are overburdened, and molecular testing is time consuming which delays reporting  
60 and that in turn limits the containment of spread. [3] Hence there is a demand for alternative testing  
61 strategies that are rapid and less sophisticated. [4].

62 In SARS-CoV-2 human-to-human transmission is through droplets or direct contact [5] and its  
63 symptoms are very similar to flu, hence molecular tests are critical to differentiate and detect  
64 COVID-19 infections. In the early stages of infection, the viral load is usually high in patients and  
65 studies show that a single swab can contain more than a million viral particles,[6] hence nucleic  
66 acid testing is the most efficient form of testing in the early stages, and identifying infections earlier  
67 is vital. As mass testing, early detection and isolation are crucial for containing the spread of  
68 infection, evaluation of these rapid tests becomes imperative.

69 Currently there are many nucleic acid detection assays that have obtained emergency authorization  
70 by FDA to detect SARS-COV-2 and have been largely implemented around the globe.  
71 The study compares seven different molecular tests that detects nuclear RNA of SARS- COV- 2  
72 and evaluates them against the standard RT-PCR.

### 73 **Materials and Methods**

74 This study obtained ethical approval from the IRB of Department of Health (DOH), Abu Dhabi.  
75 The study was conducted among people who were admitted in the COVID-19 field hospital and  
76 among people who were getting screened for COVID-19 infections in the laboratory. After getting  
77 informed consent from the participants nasopharyngeal swabs (NPS) were collected from the study  
78 participants. For the wet swab, a sterile swab was used for collection and then was placed into the  
79 universal transport medium (UTM). An additional dry swab was collected from participants who  
80 were willing to give an additional sample. All samples that were collected outside the lab were  
81 transported to the lab immediately and samples that were not processed immediately were stored  
82 at -80 degree Celsius.

83 A total of 5181 participants were tested for SARS-CoV-2 virus by the gold standard RT-PCR  
84 method for SARS-CoV-2 detection and with one of these seven rapid methods of detection. The  
85 rapid tests were evaluated by comparison the rapid nucleic acid detection assays results with the  
86 standard RT-PCR results for SARS-COV-2 detection. Of these seven rapid detection methods, two  
87 were based on loop isothermal nucleic acid amplification technology (Abbott ID NOW, AQ-TOP),  
88 one on OMEGA amplification (Atila iAMP), one direct RT-PCR without RNA extraction method  
89 (Direct NPS), one based on insulated isothermal polymerase chain reaction (iiPCR) technology,  
90 one on automated multiplex real-time RT-PCR assay (Cobas Liat) and one based on microfluidic  
91 chip-based PCR method (Genechecker).

92 **The seven rapid nucleic acid detection assays**

93 **The Abbott ID NOW COVID-19 assay [7]** - 689 samples were tested using this method. It is an  
94 automated assay that utilizes isothermal nucleic acid amplification technology for the qualitative  
95 detection of nucleic acid from the SARS-CoV-2 virus from nasopharyngeal swabs from  
96 individuals who are suspected of COVID-19. It detects the RNA-dependent RNA polymerase  
97 (RdRp) gene segment of SARS-CoV-2 and is performed on the ID NOW instrument. Fluorescently  
98 labeled molecular beacons are used to specifically identify each of the amplified RNA targets. The  
99 testing was performed as per manufacturer's instructions. It takes 1- 2 minutes active preparation  
100 and the time to result is about 13 minutes. It has received FDA emergency authorization for use.  
101 [8] In this study, the testing was done onsite for detecting SARS-COV-2 from a dry swab collected  
102 from the participants. Results are directly displayed on the screen as positive or negative along  
103 with the internal control validity.

104

105 **Atila iAMP COVID- 19 detection [9]** – 197 samples were tested using this method, which is a  
106 real-time reverse transcription based on a proprietary isothermal amplification technology termed  
107 OMEGA amplification. OMEGA primer sets are designed to specifically detect RNA and later  
108 cDNA from the N and ORF-1ab genes of the SARSCoV-2 virus in nasal, nasopharyngeal and/or  
109 oropharyngeal swabs from individuals who are suspected of COVID-19. The iAMP COVID-19  
110 assay has the ability to detect SARS-CoV-2 RNA directly from samples without prior RNA  
111 extraction process. All procedures as per manufacturer instructions were followed. The turnaround  
112 time is 60 mins. It has received FDA emergency authorization for use.[10] In this method, the  
113 control used is a human gene that is amplified and measured in the HEX channel. If a sample  
114 shows no exponential amplification curve in the HEX channel but an exponential curve in the

115 FAM channel, the sample is still reported as a valid run and will be interpreted according to  
116 manufacturers instructions. If there is no exponential amplification curve in any channel, the sample  
117 test result is termed invalid.

118

119 **AQ-Top Plus COVID-19 Rapid Detection Kit:** [11] 226 samples were run through this kit. It is  
120 a Real-Time Loop Mediated Isothermal Amplification (RT-LAMP) test intended for the  
121 qualitative detection of nucleic acid from SARS-CoV-2 in clinical respiratory specimens like  
122 nasopharyngeal swabs. The AQ-TOP COVID-19 Rapid Detection Kit PLUS uses dual-labeled  
123 Peptide Nucleic Acid (PNA) probes that target ORF1ab and N gene for detection of SARS-CoV-  
124 2 RNA. It has a fast turnaround time of 20 minutes. It has also received FDA emergency  
125 authorization for use.[12] The results are interpreted as per manufacturer's instructions. If no  
126 amplification curves are detected in both the FAM and VIC fluorescent channels or if an  
127 amplification curve is detected but at a CT more than 30 the test is considered invalid.

128

129 **Direct Nasopharyngeal Swab (Direct NPS) Realtime RT-PCR [13]:** 200 samples were tested  
130 by this method. The NPS samples collected were stored in the lab at -80 degree Celsius and was  
131 run after few days. It is an RNA-extraction free, RT-qPCR method for SARS-CoV-2 detection.

132 The direct NPS method was tested with various transport media for direct lysis. Bio-Speedy Direct  
133 RT-qPCR SARS-Cov-2 kit with the vNAT buffer contains guanidinium thiocyanate and was  
134 validated with 50 samples. 90 samples were used to validate DIAGNOVITAL Magicprep fast  
135 RNA isolation kit and 10 samples were validated with OriginSafe Viral Lysis Transport Kit, which  
136 contains Viral Lysis Transport Medium (OriginSafe VLTM) that disrupts lipid membrane and  
137 inactivates nucleases. All 3 kits were unsuccessful to produce a good quality extract and all tests

138 presented invalid results. However, direct lysis using proteinase K was relatively more successful  
139 and was pursued for evaluation. Nasal Swabs are treated with proteinase K followed by a heat  
140 inactivation step and is then directly added to the master mix for RT-qPCR. For best results,  
141 optimization of the ratio of proteinase K and the sample mixture was done in the lab, testing five  
142 different ratios starting from 5ul of the proteinase K with 50 ul of the sample sequentially to 40ul  
143 of proteinase K and 15ul of sample mixture and the best correlation with the reference values were  
144 attained at 15 ul of proteinase K with 40 ul sample. With this optimization further testing was  
145 done, turnaround time is around 2 hours.

146  
147 **Genechecker PCR system- UF 300 – RT PCR system [14]**– 1133 samples were tested in this  
148 method. It is an innovative microfluidic chip-based PCR method with a compact device and ultra-  
149 fast ramping of 40 cycles in 20 minutes through a unique thermal cycling mechanism. The kit has  
150 been developed to detect both RdRP gene and N gene of SARS-COV-2. Two fluorescent channels  
151 are used, FAM and ROX to detect the gene and to serve as an internal control respectively. The primer  
152 pairs and probes for the detection of these two target genes are pre-labeled in the wells of the test chip so  
153 that user does not have to pipette primers and probes for running the test. Four samples can be tested per  
154 run and the standard turnaround time is 45 minutes with 10 – 15 minutes of preparation.

155 The results are displayed on screen as either N gene and RdRP gene detected or not detected along  
156 with the control validity. This makes the reporting easier, and it also displays the amplification  
157 curves for easier reading. The positive control should be positive, and template control should be  
158 negative to confirm the test validity, if not the test is reported invalid.

159

160 **Cobas Liat system SARS-CoV-2 & Influenza A/B nucleic acid test [15]:** 524 samples were  
161 tested with this method. It is an automated multiplex real-time RT-PCR assay for in-vitro  
162 qualitative detection and differentiation of SARS-CoV-2, influenza A, and influenza B virus RNA  
163 in nasopharyngeal and nasal swabs. The assay targets both the ORF1 a/b non-structural region and  
164 nucleocapsid protein gene that are unique to SARS-CoV-2. An Internal Process Control (IPC) is  
165 present to control for adequate processing of the target virus through steps of sample purification,  
166 nucleic acid amplification, and to monitor the presence of inhibitors in the RT-PCR processes. The  
167 results are displayed as SARS-CoV-2 detected, not detected or invalid within 20 minutes. It has  
168 got FDA emergency authorization for use. [16]

169 **POCKIT SARS-CoV-2 (orf lab) (RT-ii PCR) assay [17]**

170 It is a PCR test for qualitative detection of SARS-CoV-2 from nasopharyngeal swabs and 2212  
171 samples were tested with this method. It uses the insulated isothermal polymerase chain reaction  
172 (iiPCR) technology and must be used with a POCKIT Central Nucleic Acid Analyzer. It generates  
173 fluorescent signals, 520 nm and 550 nm, when the specific nucleic acid sequences of SARS-CoV-  
174 2 and the internal Control are amplified, respectively. When both the 520 nm and 550 nm signals  
175 are positive the sample is interpreted positive for SARS-COV-2 and when 520 nm is negative, and  
176 550 nm is positive the sample is termed negative for SARS-COV-2 virus. When both signals are  
177 negative or not detected it is termed invalid.

178

179 **Statistical analysis**

180 The results of the standard RT – qPCR was used as a standard reference and the results obtained  
181 from the rapid methods were compared to the standard reference reports.



182 Sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and  
183 accuracy were calculated for each method. Cohen's kappa values were calculated to measure  
184 agreement, along with percent positive agreement (PPA), negative agreement percent (NPA) and  
185 overall agreement were calculated. SPSS statistical software was used for all statistical analysis.

186

187

## 188 **Results**

189 The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and  
190 accuracy were calculated for the seven rapid methods by comparing with the standard RT-PCR  
191 results. The results are shown in figure 1. (Figure 1)

192 AQ-TOP and Genechecker had the highest sensitivity and positive predictive value followed by  
193 sensitivity of Abbott ID NOW and Cobas Liat. The Direct NPS RT-qPCR method and Atila had  
194 the lowest sensitivity. The POCKIT had the highest accuracy followed by Genechecker and Cobas  
195 Liat.

196 The positive, negative, and overall agreement percentage along with Cohens' kappa value were  
197 calculated for the seven methods and are presented in Table 1.

198 The positive percentage agreement with the standard RT-qPCR was strongest with AQ-Top  
199 followed by Genechecker. Similarly, the negative agreement was best with POCKIT, Cobas Liat  
200 and Genechecker. AQTOP. The overall agreement was highest in POCKIT and the overall  
201 agreement percentage was poor in Direct PCR and Atila iAMP.

202 The number of positive cases missed, and details of the results reported invalid by the rapid tests  
203 are shown in Table 2. Atila iAMP showed the highest percentage of invalid reports missing a large  
204 proportion (44.7%) of positive cases followed by AQ-TOP with 7% invalid reports. The Direct  
205 NPS- RT-PCR and Cobas Liat did not show any invalid reports.

## 206 **Discussion**

207 In this ongoing COVID-19 pandemic with extensive transmission of infection, rapid molecular  
208 tests are very crucial for early identification and isolation. The molecular assays evaluated in this  
209 study are all rapid with low complexity thus requires less hands-on time, which is the need of the  
210 hour hence assays were evaluated in comparison to the standard RT-PCR.

211 Our study found that the sensitivity of the Atila iAMP assay and Direct lysis RT-PCR method for  
212 nasopharyngeal swab RT-qPCR was very low. While some studies have demonstrated no  
213 substantial difference in sensitivity for direct NPS method when compared to standard RT-qPCR  
214 for molecular detection of SARS-CoV-2 [18], there are also evidences that show, amplification  
215 directly from samples can reduce efficiency of PCR. [19]. This can be attributed to the presence  
216 of inhibitors that interferes with the polymerase activity and decrease the sensitivity and accuracy  
217 of detection. [20] Another reason may be due to inadequate extraction quality in the direct method,  
218 further the samples that were used in this study for the direct NPS RT-qPCR method were stored  
219 in the lab at -80 degrees Celsius for 3 – 4 days. This might be one of the reasons for low sensitivity  
220 as a study done in Germany has shown that direct NPS performs better when the samples are fresh  
221 and RNA extraction would be required if the samples are stored longer. [21]

222 The Atila iAMP assay has been claimed to have around 87% PPA and 100% NPA with the  
223 reference RT-PCR assay. [22], but in this study we found that the sensitivity was very low, and it

224 reported a large number of invalid results, missing more than 40 % of positive cases when  
225 compared to the standard RT-qPCR results. The agreement percentage (kappa agreement) with the  
226 NPS results was low. In this assay, 93 positive samples were reported as either negative or invalid  
227 and the mean Ct value of these positive samples were  $31.54 \pm 4.84$ . The test missed weak/ low viral  
228 load samples, that had Ct values more than 30. This was supported by the study in Stanford, that  
229 showed Atila had lower sensitivity and required high volume of nucleic acid eluate. [22] Further  
230 studies have shown that molecular tests using the LAMP technology have reported false negative  
231 results in low viral load. [23] However the assay showed high specificity which can be explained  
232 by the four different primers that are used in this assay to detect six different sequences of the  
233 RNA of SARS-COV-2. [24] Also the test does not require RNA extraction prior to amplification,  
234 thus reducing the time to run along with the ability to process 96 samples per run and providing  
235 the results within 60 minutes. While there are positive aspects, the sensitivity and reliability of the  
236 method are important parameters for screening, hence with lower sensitivity higher percentages of  
237 false negative results would be expected and the high percentage of invalid results makes the test  
238 less reliable as a rapid method, for these reasons the test cannot be widely employed as a screening  
239 test.

240 In our study the Abbott and AQ-TOP both used the LAMP technology and had high sensitivity,  
241 specificity, PPA, NPA and the kappa coefficient was strong. Similar studies have reported LAMP  
242 assays to be identical with the RT-PCR tests and reported similar sensitivity and specificity [25]  
243 The drawback of AQ - TOP was that it showed 6% invalid reports, which is a relatively high  
244 number compared to other tests. But this method is quick with faster amplification and high  
245 throughput, 96 samples can be tested in each run, results are easily readable and requires less

246 specialized equipment. It further has the ability for amplification of multiple targets in a single  
247 reaction.[26]

248 The Abbott ID NOW had an accuracy of 96.5%, with sensitivity and specificity comparable to the  
249 standard RT – qPCR and lowest percentage of invalid reports compared to other methods. It also  
250 showed a strong agreement with the RT-PCR results. A study by Rhoads in the USA reported  
251 similar findings, which showed that the assay had a good PPA of 94%. [27] Another study done  
252 in New York had shown that when compared to Xpert Xpress, ID NOW revealed good PPA only  
253 when sample had low Ct values and the PPA was low in the higher Ct values samples or when the  
254 viral load was low. [28] Similar reports were published by another study that validated RT-LAMP,  
255 which showed that samples having Ct values less than 30 showed 100% sensitivity, while samples  
256 with Ct values more than 35 showed only 54% concordance with the RT-qPCR results.[29]  
257 However in our study, we found that the concordance with the RT- qPCR results did not change  
258 with the Ct values. Further, the Abbott ID is compact, can be used as a bedside test and it is rapid  
259 as it detects the positive results in just 7 minutes and negative results in 13 minutes, although only  
260 one sample can be tested per run.

261 The Genechecker had a high sensitivity and concordance with the RT-qPCR reports, with the least  
262 percentage of invalid reports. It has statistically significant 0.938 Cohen’s kappa value and thereby  
263 strong agreement with the results of the standard reference test. Further this method has a  
264 turnaround time of 45 minutes and 4 samples can be tested per run. But the preparation of the  
265 samples requires 5 to 10 minutes and requires manual pipetting which is recommended to be done  
266 in a biosafety cabinet. Therefore, though Genechecker is a compact instrument cannot be used as  
267 a bedside test. Also for efficient usage four samples need to be run together as there would be

268 wastage of the kit cartridges. There aren't many studies on the evaluation of Genechecker but our  
269 study shows the method has great potential as a rapid detection method.

270 The Cobas Liat automated RT-PCR showed the PPA of 94.5 % and accuracy of 97.5% with the  
271 lowest PPV of 76% and the results can be obtained in 20 minutes . Another study that evaluated  
272 the clinical performance of Cobas Liat showed that its accuracy was 98.6%, positive percent  
273 agreement was 100% and the negative percent agreement was 97.4%. which was very similar to  
274 our study report. [30] However a recent report warns of potential false positives with Cobas rapid  
275 test that was alleged to sporadic assay tube leakage or abnormal PCR cycling in the reaction tubes.  
276 [31] This might explain the high false positives and lowest PPV observed in our study with Cobas  
277 Liat.

278 The POKKIT SARS-CoV-2 (orf lab) (RT-ii PCR) assay had the highest overall agreement with  
279 the reference RT-PCR method. The turnaround time is 85 minutes with a throughput of 8 samples  
280 per run. The positive A study that validated its clinical performance comparing it to standard RT-  
281 PCR assay also showed that positive agreement was 96.8% and kappa value of 0.93. [32] However  
282 in our study the positive agreement was only 90% this might be because the number of positive  
283 samples tested were only 75 samples compared to 2137 negative reports. The test reported high  
284 number of invalid reports which was 3.7 % of the total samples.

## 285 **Strengths and limitations**

286 The study has evaluated commercial assays available in the market for rapid detection of SARS-  
287 COV-2, which is the need of the hour. All the results are compared to the gold standard RT- PCR  
288 recommended for SARS-COV-2 detection, which gives an insight of the performance of these  
289 rapid methods based on the standard comparison.

290 The limitation is that the number of samples tested with each rapid method varies, which was based  
291 on the availability of kits and reagents.

## 292 **Conclusion**

293 In summary, the evaluation of seven rapid methods of detection of SARS-COV-2 using NPS shows  
294 that the direct (extraction free) NPS method and Atila had low sensitivity, along with the high  
295 number of invalid reports with Atila, which made the test unreliable. While AQ-TOP had good  
296 sensitivity and rapid turnaround time of 20 minutes but again the percentage of invalid reports  
297 were high using this method. The POCKIT had highest overall agreement percentage but with  
298 lower sensitivity than most other rapid tests and high number of invalid reports. AQ-TOP, Abbott  
299 and GeneChecker had high sensitivity a strong kappa value and rapid turnaround time of 20, 15  
300 and 45 minutes, respectively. Cobas Liat, Abbott ID NOW and Genechecker system had the least  
301 number of invalid reports however the throughput for each is 1,1 and 4 respectively. Further  
302 studies reviewing of all these parameters are needed, to consider implementing these rapid tests in  
303 large scale in detection of SARS-COV-2.

## 304 **Authors contribution:**

- 305 1. Sally A. Mahmoud: conceptualization, Methodology, validation, reviewing and editing,  
306 supervision and project administration
- 307 2. Esra Ibrahim : Conceptualization, Methodology, validation, reviewing and editing
- 308 3. Subhashini Ganesan: Conceptualization, Methodology, writing original draft, validation,  
309 reviewing and editing
- 310 4. Bhagyashree Thakre: Methodology, validation, reviewing and editing
- 311 5. Juliet G Teddy: Methodology, validation, reviewing and editing
- 312 6. Preeti Raheja: Methodology, validation, reviewing and editing
- 313 7. Walid Z Abbas: Reviewing, editing, supervision and project administration

## 314 **Funding statement**

315 The study was not funded by any funding body, it was done in Biogenix lab as a part of research.

### 316 **Ethics approval and consent to participate.**

317 The Ethics approval was obtained from Department of Health (DOH) Institutional review board  
318 (IRB), Abu Dhabi. All methods were carried out in accordance with relevant guidelines and  
319 regulations. The Department of Health (DOH) Institutional review board (IRB), Abu Dhabi.

### 320 **Informed consent statement**

321 Informed consent was obtained from all participants in the study.

### 322 **Data Availability**

323 The data is available with the corresponding author, Dr. Sally, Director of Biogenix G42 lab and  
324 will be produced on request.

### 325 **Conflict of interest**

326 The authors declare that they have no conflict of interest regarding the publication of this paper.

### 327 **References**

- 328 1. Worldometers. 2020. Available at: <https://www.worldometers.info/coronavirus/country/>  
329 (Accessed on 23<sup>rd</sup> February 2020)
- 330 2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, Bleicker T, Brünink  
331 S, Schneider J, Schmidt ML, Mulders DG. Detection of 2019 novel coronavirus (2019-  
332 nCoV) by real-time RT-PCR. Eurosurveillance. 2020 Jan 23;25(3):2000045.
- 333 3. WHO (World Health Organization) Laboratory testing strategy recommendations for  
334 COVID-19. Interim guidance. 2020. Available at:

- 335 [https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab\\_testing-](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-)  
336 [2020.1-eng.pdf](https://apps.who.int/iris/bitstream/handle/10665/331509/WHO-COVID-19-lab_testing-2020.1-eng.pdf) (Accessed 12 December 2020)
- 337 4. Nguyen T, Duong Bang D, Wolff A. 2019 novel coronavirus disease (COVID-19): paving  
338 the road for rapid detection and point-of-care diagnostics. *Micromachines*. 2020  
339 Mar;11(3):306.
- 340 5. Andersen, K.G., Rambaut, A., Lipkin, W.I. et al. The proximal origin of SARS-CoV-2.  
341 *Nat Med* 26, 450–452 (2020). <https://doi.org/10.1038/s41591-020-0820-9>
- 342 6. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D,  
343 Jones TC, Vollmar P, Rothe C, et al. 2020. Virological assessment of hospitalized patients  
344 with COVID-2019. *Nature* doi:10.1038/s41586-020-2196-x
- 345 7. Abbott Launches Molecular Point-of-Care Test to Detect Novel Coronavirus in as Little as  
346 Five Minutes. Available online: [https://abbott.mediaroom.com/2020-03-27-Abbott-](https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-Five-Minutes)  
347 [Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-](https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-Five-Minutes)  
348 [Five-Minutes](https://abbott.mediaroom.com/2020-03-27-Abbott-Launches-Molecular-Point-of-Care-Test-to-Detect-Novel-Coronavirus-in-as-Little-as-Five-Minutes) (accessed on 2 April 2020).
- 349 8. US Food and Drug Administration (FDA). ID NOW COVID-19. Letter of  
350 Authorization. 2020. Available at: <https://www.fda.gov/media/136522/download>
- 351 9. Atila Biosystems. iAMP COVID-19 Detection Kit. Available at:  
352 <https://atilabiosystems.com/our-products/covid-19/>
- 353 10. US Food and Drug Administration (FDA). Atila Biosystems - iAMP COVID-19 Detection  
354 Kit. Available at: <https://www.fda.gov/media/136870/download>
- 355 11. Seasun Biomaterials. AQ- TOP COVID-19 rapid series. Available at:  
356 <http://seasunbio.muee.co.kr/ko/?c=177&s=&gp=1&gbn=viewok&ix=272>



- 357 12. US Food and Drug Administration (FDA). AQ-TOP™ COVID-19 Rapid Detection Kit  
358 PLUS. 2020. <https://www.fda.gov/media/142800/download>
- 359 13. Genoud V, Stortz M, Waisman A, Berardino BG, Verner P, Dansey V, Salvatori M,  
360 Lenicov FR, Levi V. Extraction-free protocol combining Proteinase K and heat inactivation  
361 for detection of SARS-CoV-2 by RT-qPCR. medRxiv. 2020 Jan 1.
- 362 14. Global Innovation Exchange. Genechecker UF- 300 by Genesystem. Available at:  
363 [https://www.globalinnovationexchange.org/innovation/genechecker-uf-300-by-](https://www.globalinnovationexchange.org/innovation/genechecker-uf-300-by-genesystem)  
364 [genesystem](https://www.globalinnovationexchange.org/innovation/genechecker-uf-300-by-genesystem)
- 365 15. Cobas SARS-CoV-2 & Influenza A/B Assay. Available at:  
366 [https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-](https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-nucleic-acid-test.html)  
367 [nucleic-acid-test.html](https://diagnostics.roche.com/global/en/products/params/cobas-sars-cov-2-influenza-a-b-nucleic-acid-test.html)
- 368 16. US Food and Drug Administration (FDA). <https://www.fda.gov/media/142193/download>  
369 (cobas liat)
- 370 17. POCCKIT Central SARS-CoV-2 Premix Reagent- User manual. Available at:  
371 [https://www.genereach.com/data/document%20download/common/Products/POCKIT%2](https://www.genereach.com/data/document%20download/common/Products/POCKIT%20Central%20SARS-CoV-2%20Premix%20Reagent%20%20User%20Manual%20(20200601)_US%20....pdf)  
372 [0Central%20SARS-CoV-](https://www.genereach.com/data/document%20download/common/Products/POCKIT%20Central%20SARS-CoV-2%20Premix%20Reagent%20%20User%20Manual%20(20200601)_US%20....pdf)  
373 [2%20Premix%20Reagent%20 %20User%20Manual%20\(20200601\)\\_US%20....pdf](https://www.genereach.com/data/document%20download/common/Products/POCKIT%20Central%20SARS-CoV-2%20Premix%20Reagent%20%20User%20Manual%20(20200601)_US%20....pdf)
- 374 18. Srivatsan S, Han PD, van Raay K, Wolf CR, McCulloch DJ, Kim AE, Brandstetter E,  
375 Martin B, Gehring J, Chen W; Seattle Flu Study Investigators, Kosuri S, Konnick EQ,  
376 Lockwood CM, Rieder MJ, Nickerson DA, Chu HY, Shendure J, Starita LM. Preliminary  
377 support for a "dry swab, extraction free" protocol for SARS-CoV-2 testing via RT-qPCR.  
378 bioRxiv [Preprint]. 2020 Apr 23:2020.04.22.056283. doi: 10.1101/2020.04.22.056283.  
379 PMID: 32511368; PMCID: PMC7263496.

- 380 19. Wee SK, Sivalingam SP, Yap EPH. Rapid Direct Nucleic Acid Amplification Test without  
381 RNA Extraction for SARS-CoV-2 Using a Portable PCR Thermocycler. *Genes*. 2020;  
382 11(6):664. <https://doi.org/10.3390/genes11060664>
- 383 20. Hall, A.T.; Zovanyi, A.M.; Christensen, D.R.; Koehler, J.W.; Minogue, T.D. Evaluation of  
384 Inhibitor-Resistant Real-Time PCR Methods for Diagnostics in Clinical and  
385 Environmental Samples. *PLoS ONE* 2013, 8, e73845
- 386 21. Lübke N, Senff T, Scherger S, Hauka S, Andrée M, Adams O, Timm J, Walker A.  
387 Extraction-free SARS-CoV-2 detection by rapid RT-qPCR universal for all primary  
388 respiratory materials. *Journal of Clinical Virology*. 2020 Sep 1;130:104579
- 389 22. Bulterys PL, Garamani N, Stevens B, Sahoo MK, Huang C, Hogan CA, Zehnder J, Pinsky  
390 BA. Comparison of a laboratory-developed test targeting the envelope gene with three  
391 nucleic acid amplification tests for detection of SARS-CoV-2. *Journal of Clinical Virology*.  
392 2020 Aug 1;129:104427.
- 393 23. Zhen W, Smith E, Manji R, Schron D, Berry GJ. Clinical evaluation of three sample-to-  
394 answer platforms for detection of SARS-CoV-2. *Journal of clinical microbiology*. 2020 Jul  
395 23;58(8).
- 396 24. Kitagawa, Y., Orihara, Y., Kawamura, R., Imai, K., Sakai, J., Tarumoto, N., ... Maeda, T.  
397 (2020). Evaluation of rapid diagnosis of novel coronavirus disease (COVID-19) using  
398 loop-mediated isothermal amplification. *Journal of Clinical Virology*,  
399 104446. doi:10.1016/j.jcv.2020.104446
- 400 25. Yan C, Cui J, Huang L, Du B, Chen L, Xue G, Li S, Zhang W, Zhao L, Sun Y, et al. 2020.  
401 Rapid and visual detection of 2019 novel coronavirus (SARS-CoV-2) by a reverse

- 402 transcription loop-mediated isothermal amplification assay. *Clin Microbiol Infect*  
403 doi:10.1016/j.cmi.2020.04.001
- 404 26. 31Esbin MN, Whitney ON, Chong S, Maurer A, Darzacq X, Tjian R. Overcoming the  
405 bottleneck to widespread testing: a rapid review of nucleic acid testing approaches for  
406 COVID-19 detection. *Rna*. 2020 Jul 1;26(7):771-83.
- 407 27. Rhoads DD, Cherian SS, Roman K, Stempak LM, Schmotzer CL, Sadri N. Comparison of  
408 Abbott ID Now, Diasorin Simplexa, and CDC FDA EUA methods for the detection of  
409 SARS-CoV-2 from nasopharyngeal and nasal swabs from individuals diagnosed with  
410 COVID-19. *Journal of clinical microbiology*. 2020 Apr 17
- 411 28. Basu A, Zinger T, Inglema K, Woo KM, Atie O, Yurasits L, See B, Agüero-Rosenfeld ME.  
412 Performance of Abbott ID Now COVID-19 rapid nucleic acid amplification test using  
413 nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New  
414 York City academic institution. *Journal of clinical microbiology*. 2020 Jul 23;58(8).
- 415 29. Haq F, Sharif S, Khurshid A, Shabbir I, Salman M, Badar N, Ikram A, Ahad A, Malik MF.  
416 Development Optimization and Validation of RT-LAMP based COVID-19 Facility in  
417 Pakistan. *bioRxiv*. 2020 Jan 1.
- 418 30. Hansen G, Marino J, Wang ZX, Beavis KG, Rodrigo J, Labog K, Westblade LF, Jin R,  
419 Love N, Ding K, Garg S, Huang A, Sickler J, Tran NK. Clinical Performance of the Point-  
420 of-Care cobas Liat for Detection of SARS-CoV-2 in 20 Minutes: a Multicenter Study. *J*  
421 *Clin Microbiol*. 2021 Jan 21;59(2):e02811-20.
- 422 31. US Food and Drug Administration (FDA). [https://www.fda.gov/medical-devices/letters-](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery)  
423 [health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery)  
424 [cov-2-influenza-test-use-cobas-liat?utm\\_medium=email&utm\\_source=govdelivery](https://www.fda.gov/medical-devices/letters-health-care-providers/potential-false-results-roche-molecular-systems-inc-cobas-sars-cov-2-influenza-test-use-cobas-liat?utm_medium=email&utm_source=govdelivery)

425 32. Chang PL, Lin CY, Chen CP, Lin YC, Hu HC, Cheng SH, Cheng CY. Clinical validation  
426 of an automated reverse transcription-insulated isothermal PCR assay for the detection of  
427 severe acute respiratory syndrome coronavirus 2. *Journal of Microbiology, Immunology*  
428 *and Infection*. 2021 Feb 1.

429

430

431

432


433

434

435

436

437 **Figure 1: Comparison of the seven rapid methods of nucleic acid detection**



438

439

440 **Table 1 : Shows the agreement of the rapid tests results with the standard reference test**  
 441 **results**

Molecular assays (n)	Standard reference test		Kappa (k) (p value)	Positive agreement (%)	Negative agreement (%)	Overall Agreement (%)
	Positive	Negative				
<b>Direct NPS RT-PCR (200)</b>						
Positive	31	0	0.398	36.47	100	73
Negative	54	115	(<0.001)			
<b>Atila iAMP (127)</b>						
Positive	30	2	0.391	44.11	96.61	68.50
Negative	38	57	(<0.001)			
<b>AQ – Top (212)</b>						
Positive	102	4	0.943	98.07	96.29	91.15
Negative	2	104	(<0.001)			

<b>Genechecker (1128)</b>						
Positive	120	8	0.938	95.23	99.20	98.75
Negative	6	994	(<0.001)			
<b>Abbott ID NOW (686)</b>						
Positive	158	16	0.906	95.18	96.92	96.50
Negative	8	504	(<0.001)			
<b>Cobas Liat (524)</b>						
Positive	35	11	0.830	94.59	97.74	97.52
Negative	2	476	(<0.001)			
<b>POCKIT (2131)</b>						
<b>Positive</b>	65	8	0.893	90.27	99.61	99.29
<b>Negative</b>	7	2051	(<0.001)			

442

443

444 **Table 2: Invalid reports and positive cases missed by the rapid methods.**

<b>Rapid methods (n)</b>	<b>Invalid reports (n(%))</b>	<b>Positive cases reported by standard RT-qPCR missed by the rapid tests (n (%))</b>
Direct Nasopharyngeal Swab Realtime RT-PCR (200)	0	0
Atila iAMP COVID- 19 detection (197)	70 (35.5)	55 (44.7)
AQ-TOP COVID-19 Rapid Detection (226)	14 (6.1)	3 (2.8)
Genechecker- UF 300 – RT PCR system (1133)	5 (0.4)	5 (3.1)
The Abbott ID NOW COVID-19 assay (689)	3 (0.4)	2 (1.2)

Cobas Liat (524)	0	0
POCKIT SARS-CoV-2 (orf lab) Premix Reagent (2212)	81 (3.7)	10(1.3)

445